The Custom Recombinant Protein Production Services Market, estimated at USD 6.09 Bn in 2025, is expected to exhibit a CAGR of 11.5% and reach USD 13.05 Bn by 2032.
The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.
Recombinant proteins include recombinant Human growth hormone, interferon, interleukins, blood clotting factors, tumor necrosis factors, thrombolytic drugs, and enzymes for treating major diseases such as diabetes, dwarfism, congestive heart failure, myocardial infarction, cerebral apoplexy, neutropenia, multiple sclerosis, thrombocytopenia, hepatitis, anemia, Crohn’s disease, rheumatoid arthritis, asthma, cancer, which is expected to drive market growth over the forecast period. Thus, the increasing prevalence of such diseases is expected to drive market growth. For instance, according to the data provided by Breastcancer.org, in March 2025, an estimated 287,850 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 51,400 new cases of non-invasive (in situ) breast cancer.
Global Custom Recombinant Protein Production Services Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
The COVID-19 outbreak was first reported on December 31, 2025 in Wuhan, China. For instance, according to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 770 million cases and 6.9 million deaths due to the Coronavirus (COVID-19) were reported up until August 27, 2025, across the globe.
The COVID-19 pandemic has drastically affected research and development activities across the globe. The capacity of the lab is reduced due to disruptions observed in product development for adjustment in remote work environments. According to the clinicaltrial.gov, as of April 2025, there were over 2,850 ongoing trials, and around 900,000 patients were enrolled in regions that were in partial or complete lockdown due to COVID-19 restrictions at the trial sites. Several Research and developmemt labs are operating at below 50% of normal capacity.
Global Custom Recombinant Protein Production Services Market: Key Developments
Increasing research and development in the field of life sciences is also expected to aid in the growth of the custom recombinant protein production services market over the forecast period. For instance, in October 2025, ATUM, a leading global manufacturing and contract development organization (CDMO) for biopharmaceuticals and Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) focused on the development and manufacturing of biopharmaceuticals, signed a full license agreement for the Leap-in transposase platform. The Leap-In Transposase platform is a bioengineered solution for the efficient, fast, robust, and stable expression of recombinant proteins in mammalian cells.
Browse 26 market data tables and 29 figures spread through 180 Pages and in-depth TOC on “Global Custom Recombinant Protein Production Services Market”- Forecast to 2032, Global Custom Recombinant Protein Production Services Market, By Expression System (Mammalian, Bacteria, Insect, Yeast, and Others), By End User (Research Institutes, Biotechnology and Pharmaceutical Companies, Contract Research Organizations and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Custom Recombinant Protein Production Services Market:
- The global custom recombinant protein production services market is expected to exhibit a CAGR of 11.5% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global custom recombinant protein production services market.
- Among expression system, the mammalian segment is expected to hold a dominant position in the global custom recombinant protein production services market during the forecast period, and this is attributed to inorganic activities among market players. For instance, the Estonian biopharmaceutical innovator Icosagen AS has reached a US$19.2 million financing agreement with the European Investment Bank (EIB) backed by the InvestEU programme to further strengthen its drug discovery, development, and production services. The funds are part of Icosagen's US$42.7 million investment into increasing its innovative contract research and development capabilities as well as into a new current good manufacturing practice (cGMP) facility to produce innovative drugs for clinical trials. This new facility will help Icosagen become a one-stop shop for its biotechnology and pharmaceutical clients, and a full contract research, development, and manufacturing organization (CRDMO), offering seamless discovery, development, and manufacturing capabilities of mammalian protein drug candidates.
- Among region, North America is expected to be the dominant region in the global custom recombinant protein production services market, owing to increasing acquisitions by market players in the region. For instance, in January 2025, Thermo Fisher Scientific Inc., a company based in the U.S. that provides scientific equipment, reagents, and consumables as well as software services, and PeproTech, Inc., a company based in New Jersey, U.S., that develops and produces recombinant proteins such as cytokines and growth factors, announced that Thermo Fisher completed its acquisition of PeproTech on December 30, 2025, for a total cash purchase price of around US$1.85 billion.
- Major players operating in the global custom recombinant protein production services market are GenScript Biotech Corporation, SignalChem Biotech Inc., Crown Bioscience, Inc., BPS Bioscience Inc., Novoprotein, Applied Biological Materials (abm) Inc., Eurofins Pharma Discovery Services, Abgent (WuXi AppTec Company), OriGene Technologies, Inc., Kempbio, Inc., Trenzyme GmbH, Sino Biological Inc., Aragen Bioscience, a GVKBIO Company, LakePharma, Inc., , Proteos Inc., Icosagen AS, Novus Biological LLC, Proteogenix, Premas Biotech, ATUM, and Aldevron
Contact Us